Holen Sie sich die Stockscreener-App
99.22
0.32%
0.32
Handel nachbörslich:
99.63
0.41
+0.41%
Schlusskurs vom Vortag:
$98.90
Offen:
$98.36
24-Stunden-Volumen:
5.25M
Relative Volume:
0.85
Marktkapitalisierung:
$146.43B
Einnahmen:
$16.75B
Nettoeinkommen (Verlust:
$1.85B
KGV:
79.38
EPS:
1.25
Netto-Cashflow:
$2.37B
1W Leistung:
+3.87%
1M Leistung:
-5.82%
6M Leistung:
+20.16%
1J Leistung:
+47.56%
1-Tages-Spanne:
$97.93
$99.41
1-Wochen-Bereich:
$94.85
$99.41
52-Wochen-Spanne:
$66.80
$107.17
Boston Scientific Corp Stock (BSX) Company Profile
Firmenname
Boston Scientific Corp
Sektor
Branche
Telefon
508-683-4000
Adresse
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Vergleichen Sie BSX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
99.22 | 146.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
ABT
Abbott Laboratories
|
126.30 | 219.05B | 41.95B | 13.40B | 6.35B | 7.65 |
|
SYK
Stryker Corp
|
375.91 | 143.44B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.21 | 118.24B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.34 | 41.35B | 5.72B | 4.17B | 259.90M | 6.97 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Herabstufung | Needham | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-20 | Fortgesetzt | Citigroup | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-05-27 | Hochstufung | Needham | Hold → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-26 | Herabstufung | Needham | Buy → Hold |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-17 | Eingeleitet | Truist | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Buy |
| 2019-12-30 | Bestätigt | Cowen | Outperform |
| 2019-12-19 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-09-05 | Fortgesetzt | JP Morgan | Overweight |
| 2019-09-03 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-10-02 | Bestätigt | Morgan Stanley | Overweight |
| 2018-09-07 | Bestätigt | Needham | Strong Buy |
| 2018-09-04 | Hochstufung | Jefferies | Hold → Buy |
| 2018-07-06 | Bestätigt | Needham | Strong Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-04-26 | Bestätigt | Needham | Strong Buy |
Alle ansehen
Boston Scientific Corp Aktie (BSX) Neueste Nachrichten
Boston Scientific (BSX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Neurotech Devices Market Is Booming Worldwide 2025-2032 | - openPR
Boston Scientific’s SWOT analysis: medtech giant’s stock poised for growth By Investing.com - Investing.com South Africa
Boston Scientific’s SWOT analysis: medtech giant’s stock poised for growth - Investing.com
Neurosurgery Market Size to Reach USD 6.8 Billion by 2034, Growing at 4.5% CAGR with Technological Advancements and Rising Focus on Personalized Medicine – Analysis by TMR - GlobeNewswire Inc.
Boston Scientific (BSX) Gains As Market Dips: What You Should Know - Yahoo Finance
Boston Scientific (NYSE:BSX) Sees 4% Price Rise Following Strong Earnings Report - Yahoo Finance
Boston Scientific Gains 42.2% in a Year: What's Driving the Stock? - Yahoo Finance
Boston Scientific price target raised to $110 from $100 at Bernstein - MSN
Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX) - Yahoo Finance
4C raises $175M for mitral valve technology - BioWorld Online
Boston Scientific Corp. stock underperforms Thursday when compared to competitors - MarketWatch
How Boston Scientific (sort of) became ‘Minnesota Scientific’ - Star Tribune
Boston Scientific at TD Cowen Conference: Strategic Growth Insights - Investing.com
Boston Scientific (BSX) Gains But Lags Market: What You Should Know - Yahoo Finance
Ajax, Boston Sci partner to develop new heart failure treatment - BioWorld Online
Boston Scientific Stock: Is BSX Outperforming the Healthcare Sector? - Nasdaq
Insider Sell: Jeffrey Mirviss Sells 13,022 Shares of Boston Scie - GuruFocus.com
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views? - Yahoo Finance
Boston Scientific Stock: Is BSX Outperforming The Healthcare Sector? - Barchart
Five things you need to know, and going for a chilly swim - The Business Journals
Boston Scientific buys Tivus system developer SoniVie in $540m deal - Medical Device Network
Boston Scientific Buying $600M Ultrasound System Developer - Law360
Boston Scientific to acquire Sonivie for up to $600M - BioWorld Online
Beyond The Numbers: 17 Analysts Discuss Boston Scientific Stock - Benzinga
Boston Scientific makes second acquisition for $360M upfront - The Business Journals
Boston Scientific to Purchase SoniVie Ltd. - MPO-mag
Boston Scientific to acquire renal denervation company SoniVie - Mass Device
Boston Scientific Announces Agreement To Acquire Sonivie Ltd -March 03, 2025 at 08:55 am EST - Marketscreener.com
Boston Scientific to acquire remaining 90% stake of SoniVie for $360M - TipRanks
Boston Scientific To Buy SoniVie For Upfront Payment Of Approx. $360 Mln - Nasdaq
Boston Scientific announces agreement to acquire SoniVie Ltd. - Quantisnow
The Zacks Analyst Blog The Goldman Sachs, The Progressive, Boston Scientific and Cooper-Standard - Zacks Investment Research
Boston Scientific Corporation entered into a definitive agreement to acquire remaining 90% stake in SoniVie Ltd for $540 million. - Marketscreener.com
Cavalier Investments LLC Raises Stock Holdings in Boston Scientific Co. (NYSE:BSX) - MarketBeat
Bank of New York Mellon Corp Has $1.11 Billion Stock Holdings in Boston Scientific Co. (NYSE:BSX) - MarketBeat
Top Stock Reports for Goldman Sachs, Progressive & Boston Scientific - Yahoo Finance
Boston Scientific Stock Price | BSX Stock Quote, News, and History - Markets Insider
Insider Selling: Boston Scientific Co. (NYSE:BSX) EVP Sells 4,675 Shares of Stock - MarketBeat
Consilium Wealth Advisory LLC Raises Holdings in Boston Scientific Co. (NYSE:BSX) - MarketBeat
April 11th Options Now Available For Boston Scientific (BSX) - Nasdaq
Boston Scientific Corporation (BSX): Among Stocks to Invest In from Israel Englander’s Portfolio - Insider Monkey
Boston Scientific Co. (NYSE:BSX) Shares Acquired by Alecta Tjanstepension Omsesidigt - MarketBeat
New York Life Investment Management LLC Raises Holdings in Boston Scientific Co. (NYSE:BSX) - MarketBeat
Fisher Funds Management LTD Buys New Holdings in Boston Scientific Co. (NYSE:BSX) - MarketBeat
Boston Scientific Announces Completion Of EUR1.5 Billion Offering Of Senior Notes - Marketscreener.com
Boston Scientific announces completion of €1.5 billion offering of senior notes - Quantisnow
Catheter Market Global Report and Company Analysis 2025-2033 Featuring Abbott Laboratories, BD and Co, Boston Scientific, Teleflex, Medtronic, Johnson & Johnson, Edwards Lifesciences, Stryker - Yahoo Finance
Boston Scientific's SWOT analysis: innovative medtech stock poised for growth - Investing.com
$1000 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today - Benzinga
Boston Scientific Recalls Accolade Pacemaker Devices - The Rochester Sentinel
Finanzdaten der Boston Scientific Corp-Aktie (BSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):